UBS shareholders are facing a pivotal week, with billions in potential capital requirements and a promised $3 billion share repurchase program hanging in the balance. The Swiss Federal Council is poised to issue two key ordinances, with decisions expected on April 22 or 29, that will define the bank’s capital landscape and its ability to return cash to investors.
The core issue is a proposed rule that would require UBS to fully back its foreign subsidiaries with high-quality CET1 capital, a move analysts say could cost the bank up to $22 billion. A specific clause within this ordinance could force UBS to inject approximately $3 billion in fresh capital into its Swiss unit—a sum that matches precisely the volume earmarked for share buybacks in 2026. The bank has stated these repurchases will be executed in full only if the new capital requirements are not implemented in their strictest form.
This regulatory overhang has kept a lid on the stock since April 2024, contributing to a year-to-date decline of nearly 8% despite a powerful 40% rally from its low in June 2025. The shares currently trade at €37.08, above their 200-day moving average of €35.00.
In a move reflecting the high stakes, Barclays upgraded UBS stock from ‘Underweight’ to ‘Equal Weight’ on April 20. Analyst Flora Bocahut cited an improved risk-reward dynamic, reduced integration risks from the Credit Suisse takeover, and a less demanding valuation after recent share price weakness. The firm set a new price target of 34 Swiss Francs, one Franc higher than before. However, Barclays stopped short of an ‘Overweight’ rating, pointing to lingering uncertainty over the foreign subsidiary rules, ongoing AT1 bond litigation, and weak net new money growth in US wealth management.
The first of the two expected ordinances concerns intangible capital components. Analysts at Bank of America anticipate that deferred tax assets may be allowed to account for up to 10% of CET1 capital. This adjustment alone could reduce the estimated capital burden from $10.8 billion to $6.2 billion.
Should investors sell immediately? Or is it worth buying UBS?
The ultimate decision rests with the Swiss parliament. The Economic Affairs Committee of the Council of States will debate the banking law on May 4. Both economic committees had previously warned against over-regulation in autumn 2025, cautioning that overly stringent rules could threaten the competitiveness of the Swiss financial center, leaving room for lawmakers to potentially soften the final regulations.
Shareholders recently signaled strong support for the bank’s capital return policy. At the Annual General Meeting on April 15, a resolution to cancel shares repurchased in 2024 passed with 94% approval. The board also gained significant regulatory expertise with the election of new members: Markus Ronner as Vice-Chairman, former Apple CFO Luca Maestri, and Agustín Carstens, the former head of the Bank for International Settlements. Notably, Chairman Colm Kelleher received the lowest approval rate among all candidates at 88%, a figure viewed in Swiss banking circles as a pointed signal.
Underpinning the debate is a successful integration of Credit Suisse. UBS has confirmed it remains on track to substantially complete the merger by the end of 2026. Cumulative gross cost savings have reached $10.7 billion, exceeding the interim target of around $10 billion a quarter early and representing 77% of the total $13 billion goal. Approximately 85% of former Credit Suisse client accounts in Switzerland are now running on the UBS platform.
The regulatory verdict will be swiftly followed by another critical test: UBS is scheduled to release its first-quarter 2026 results on April 29. The confluence of these two events will determine whether the planned $3 billion can flow back to shareholders or be redirected to meet new capital demands.
Ad
UBS Stock: Buy or Sell?! New UBS Analysis from April 22 delivers the answer:
The latest UBS figures speak for themselves: Urgent action needed for UBS investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 22.
UBS: Buy or sell? Read more here...
